Drug Trial Radar · NCT06392386
A Study of Efgartigimod PH20 SC in Children Between 2 and Less Than 18 Years of Age With Generalized Myasthenia Gravis
Last checked: Nov 19, 2026Latest source record: Sep 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
12
Planned (sponsor's estimate)
Start
Jun 28, 2024
Primary completion
Sep 2027
Study completion Sep 2027
Sponsor
- Lead sponsor
- argenxargenx (ARGX)
- Sponsor type
- Industry
- First posted
- Apr 30, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 2 years, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to measure the pharmacokinetics (PK), pharmacodynamics (PD), safety, tolerability, and immunogenicity of efgartigimod PH20 SC in pediatric participants with gMG aged 2 to \<18 years. The primary goal is to confirm an appropriate dose of efgartigimod PH20 SC for pediatric patients using PK and PD results from this study. Participants will receive injections of efgartigimod PH20 SC and will be monitored for safety until the end of the study. At the end of the follow-up period, eligible participants may roll over to an open-label extension (OLE) study. The participants will be in the study for up to 14 weeks.
Conditions
- Generalized Myasthenia Gravis
Interventions
Efgartigimod PH20 SCBiological
Subcutaneous injections
Primary outcomes
What the sponsor says the trial is designed to measure.
- Efgartigimod serum concentrations as input for compartmental, model-driven analysis to determine age and size dependency of Clearance (CL)Time frame: Up to 12 weeks
- Efgartigimod serum concentrations as input for compartmental, model-driven analysis to determine age and size dependency of Volume Distribution (Vd)Time frame: Up to 12 weeks
- Total G immunoglobulins (IgG) levels as input for pharmacokinetics (PK)/pharmacodynamics (PD) modelling analysisTime frame: Up to 12 weeks
- Anti-acetylcholine receptors antibodies (AChR-Ab) as input for pharmacokinetics (PK)/ pharmacodynamics (PD) modelling analysisTime frame: Up to 12 weeks
Locations
22 sites in 14 countries. Site status is shown where the registry gives one.
Carolinas HealthCare System Neurosciences Institute - Neurology
Charlotte, North Carolina · Active not recruiting
Neurology Rare Disease Center
Denton, Texas · Active not recruiting
University of Virginia
Charlottesville, Virginia · Active not recruiting
Sydney Children's Hospital
Randwick, Australia · Recruiting
Royal Children's Hospital Melbourne
Melbourne, New South Wales, Australia · Recruiting
UZ Gent
Ghent, Belgium · Recruiting
Childrens Hospital of Eastern Ontario
Ottawa, Canada · Recruiting
Fakultni nemocnice Brno
Brno, Czechia · Recruiting
Fakultni nemocnice Ostrava
Ostrava, Czechia · Recruiting
AP-HM- Hôpital de La Timone
Marseille, France · Recruiting
Universitätsklinikum Essen
Essen, Germany · Recruiting
Hadassah Medical Center- Ein Kerem
Jerusalem, Israel · Recruiting
Schneider Children's Medical Center of Israel
Petah Tikvah, Israel · Recruiting
Tel Aviv Sourasky Medical Center Ichilov
Tel Aviv, Israel · Recruiting
Istituto G Gaslini Ospedale Pediatrico IRCCS
Genova, Italy · Recruiting
Leiden University Medical Center
Leiden, Netherlands · Recruiting
Uniwersyteckie Centrum Kliniczne w Gdansku
Gdansk, Poland · Recruiting
Neurologia Śląska Centrum Medyczne
Katowice, Poland · Recruiting
Centralny Szpital Kliniczny - Uniwersyteckie Centrum Kliniczne WUM
Warsaw, Poland · Recruiting
Hospital Universitari i Politecnic La Fe de Valencia
Valencia, Spain · Recruiting
Hôpital Nestlé
Lausanne, Switzerland · Recruiting
Oxford Children's Hospital
Oxford, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.